LeMaitre Vascular (NASDAQ:LMAT) Downgraded by StockNews.com to “Hold”

LeMaitre Vascular (NASDAQ:LMATGet Free Report) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

Several other brokerages have also commented on LMAT. KeyCorp initiated coverage on LeMaitre Vascular in a research note on Tuesday, February 6th. They set a “sector weight” rating for the company. Stifel Nicolaus upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. Barrington Research lifted their target price on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Finally, JMP Securities raised their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research report on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and an average target price of $73.83.

Get Our Latest Stock Analysis on LMAT

LeMaitre Vascular Price Performance

Shares of LMAT stock opened at $76.13 on Friday. LeMaitre Vascular has a 1-year low of $44.27 and a 1-year high of $76.24. The firm’s 50-day simple moving average is $66.84 and its 200-day simple moving average is $59.81. The firm has a market cap of $1.71 billion, a P/E ratio of 50.42, a PEG ratio of 2.32 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMATGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The company had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. During the same quarter last year, the firm posted $0.27 earnings per share. LeMaitre Vascular’s revenue was up 13.6% on a year-over-year basis. Analysts expect that LeMaitre Vascular will post 1.78 earnings per share for the current fiscal year.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 36,600 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $68.03, for a total transaction of $2,489,898.00. Following the sale, the chief executive officer now directly owns 2,187,526 shares of the company’s stock, valued at $148,817,393.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO George W. Lemaitre sold 36,600 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $68.03, for a total transaction of $2,489,898.00. Following the completion of the transaction, the chief executive officer now directly owns 2,187,526 shares of the company’s stock, valued at $148,817,393.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Joseph P. Pellegrino, Jr. sold 36,967 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $69.76, for a total value of $2,578,817.92. Following the completion of the sale, the chief financial officer now directly owns 6,452 shares in the company, valued at approximately $450,091.52. The disclosure for this sale can be found here. Insiders have sold 195,967 shares of company stock worth $14,072,324 over the last ninety days. 10.79% of the stock is owned by insiders.

Institutional Trading of LeMaitre Vascular

Large investors have recently modified their holdings of the company. Shaker Investments LLC OH boosted its stake in LeMaitre Vascular by 1.3% during the 1st quarter. Shaker Investments LLC OH now owns 13,658 shares of the medical instruments supplier’s stock valued at $906,000 after purchasing an additional 169 shares during the period. Exchange Traded Concepts LLC boosted its position in shares of LeMaitre Vascular by 0.8% during the fourth quarter. Exchange Traded Concepts LLC now owns 23,656 shares of the medical instruments supplier’s stock worth $1,343,000 after buying an additional 187 shares during the period. Riverwater Partners LLC grew its stake in shares of LeMaitre Vascular by 2.5% in the fourth quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock worth $466,000 after purchasing an additional 198 shares in the last quarter. Albion Financial Group UT increased its stake in LeMaitre Vascular by 5.6% during the 1st quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock valued at $264,000 after buying an additional 212 shares during the period. Finally, Texas Permanent School Fund Corp raised its position in shares of LeMaitre Vascular by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock worth $1,151,000 after buying an additional 225 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

About LeMaitre Vascular

(Get Free Report)

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Featured Stories

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.